| Literature DB >> 23251410 |
Ana-Maria Buga1, Claus Jürgen Scholz, Senthil Kumar, James G Herndon, Dragos Alexandru, Gabriel Radu Cojocaru, Thomas Dandekar, Aurel Popa-Wagner.
Abstract
BACKGROUND: Because most human stroke victims are elderly, studies of experimental stroke in the aged rather than the young rat model may be optimal for identifying clinically relevant cellular responses, as well for pinpointing beneficial interventions. METHODOLOGY/PRINCIPALEntities:
Mesh:
Year: 2012 PMID: 23251410 PMCID: PMC3521001 DOI: 10.1371/journal.pone.0050985
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Heatmap of genes differentially expressed between post-stroke and naïve animals.
Scaled expression values of all 1,658 differentially expressed genes are shown for each group with light red being the lowest and light green the highest expression level. The depicted dendrograms cluster samples (top) and genes (left) employing average agglomeration and euclidian distance measure.
Figure 2Correspondence analysis of differentially expressed genes and samples grouped by animal age.
The left panel depicts the Eigenvalues of the correspondence analysis and shows that the major factors contributing to the variance of stroketomics analysis were stroke (52%), post-stroke time (25%) and age (12%). (Right panel): The first two sources of variability, stroke and post-stroke time formed the coordinates of the right panel. The graph shows the distribution of transcripts (black dotes) as a function of treatment (stroke) and post-stroke time. Samples from young (green) and aged (red) animals particularly differ in their post-stroke response (illustrated by ellipses that form non-parallel planes). Transcripts with characteristic expression in naive samples are encircled in black.
Figure 3Venn diagrams for 3d and 14d post-stroke showing genes that were up- or down-regulated exclusively in old or young rats, or in both age groups.
Note that at 14 days post-stroke, the differences between the age groups were more pronounced.
Figure 4Patterns of gene expression after stroke.
There were several distinct patterns of gene regulation: persistently upregulated (black line), transiently upregulated, (orange line), “late-upregulated” (red line), “late-downregulated” (yellow line), transiently downregulated (blue line), and persistently downregulated (green line). Aged animals showed larger numbers than young of genes that were late-upregulated, persistently upregulated and persistently downregulated. The young rats, in contrast, had a much larger number of transiently upregulated and delayed downregulated genes. Note that this representation does not take into account the fold changes for individual genes but the relative change in gene expression at days 3 and 14 post-stroke.
Gene expression for several new potential therapeutic targets to improve post-stroke recovery in aged animals.
| Gene Symbol | Function | Drug availability | Y/3d | Y/14d | A/3d | A/d 14d |
|
| post-stroke inflammation | inhibitor available |
|
|
|
|
|
| post-stroke excitotoxicity | agonist not available |
|
|
|
|
|
| calcium-channel disregulation | agonist not available |
|
|
|
|
|
| calcium-channel disregulation | agonist not available |
|
|
|
|
|
| neuropathic syndrome; anxiety; depression | drugs available |
|
|
|
|
|
| post-stroke blood pressure control | drugs available |
|
|
|
|
|
| limits inflammatory reaction | drugs available |
|
|
|
|
|
| limits inflammatory reaction | drug available |
|
|
|
|
|
| post-stroke fibrosis | drug available |
|
|
|
|
|
| limits inflammatory reaction | drugs available |
|
|
|
|
|
| post-stroke inhibitory neurotransmission | agonist available |
|
|
|
|
|
| pain; sleep homeostasis | agonist available |
|
|
|
|
|
| post-stroke anxiety disorders and stress | under development |
|
|
|
|
|
| post-stroke anxiety disorders and stress | under development |
|
|
|
|
|
| post-stroke blood pressure control | drugs available |
|
|
|
|
|
| blood vessel morphogenesis | drugs available |
|
|
|
|
|
| post-stroke inflammation | drugs available |
|
|
|
|
|
| neuropathic syndrome; anxiety; depression | drugs available |
|
|
|
|
|
| calcium retrieval disregulation | agonist available |
|
|
|
|
|
| extracellular matrix component | drugs available |
|
|
|
|
|
| tissue remodeling | drug available |
|
|
|
|
|
| tissue remodeling | drug available |
|
|
|
|
|
| neuroprotection | modulator available |
|
|
|
|
|
| neuropathic syndrome; anxiety; depression | agonists available |
|
|
|
|
|
| blood pressure control | drugs available |
|
|
|
|
|
| sodium homeostasis | modulators available |
|
|
|
|
|
| calcium retrieval disregulation | modulators available |
|
|
|
|
|
| neuroprotection | modulator available |
|
|
|
|
Legend
↔ no changes vs contralateral side.
↑ upregulated vs contralateral side.
↓ downregulated vs contralateral side.
y/3d Young, 3d post-stroke.
y/14d Young, 14d post-stroke.
A/3d Aged, 3d post-stroke.
A/14d Aged, 14d post-stroke.
Confirmation of arrays data for new stroke-related genes was done by RT-PCR. Modulation of gene/protein activity by the indicated drugs may, in combination or alone, improve post-stroke recovery in aged animals. For most of the upregulated genes there is a therapeutic option but not for downregulated genes.
Figure 5Patterns of gene expression for stroke-relevant processes.
Most classes of these new genes were upregulated, with the exception of “CNS physiology & homeostasis” and “Neurogenesis & synaptic plasticity” which also displayed a large number of downregulated genes.